Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
National Cancer Institute · National Institutes of Health · +7 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
852
total citations
- FWCI
- 18.90
- Percentile
- 100%
- References
- 48
Citations per year
Authors
17Topics & keywords
Topics
Keywords
- Pharmacodynamics
- Pharmacokinetics
- Dosing
- Medicine
- Nausea
- Pharmacology
- Internal medicine
- Cmax
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.